PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29673286-7 2018 Consistently, serum inflammatory mediators TNF-alpha and IL-6 were decreased by the treatment of LPS combined with 3-MA as compared with LPS alone, while administration of LPS combined with rapamycin increased the serum TNF-alpha and IL-6 levels. Sirolimus 190-199 interleukin 6 Mus musculus 234-238 26147250-8 2015 Reduced IL1A diminished NF-kappaB transcriptional activity, which controls much of the SASP; exogenous IL1A restored IL6 secretion to rapamycin-treated cells. Sirolimus 134-143 interleukin 6 Mus musculus 117-120 28333137-8 2017 Adoptive transfer of rapamycin-treated MDSCs also downregulated the serum levels of IL-1beta, IL-6 and IFN-gamma and upregulated the serum levels of TGF-beta1 compared with the IR group and PBS-treated MDSC group. Sirolimus 21-30 interleukin 6 Mus musculus 94-98 26053964-7 2015 In addition, rapamycin reduced the production of IL-6 and IL-13 by eosinophils. Sirolimus 13-22 interleukin 6 Mus musculus 49-53 28182002-0 2017 Rapamycin upregulates glutamate transporter and IL-6 expression in astrocytes in a mouse model of Parkinson"s disease. Sirolimus 0-9 interleukin 6 Mus musculus 48-52 28182002-5 2017 Rapamycin increased interleukin-6 (IL-6) expression, which was associated with reduced expression of inflammatory cytokines, indicating anti-inflammatory properties of IL-6 in the MPTP model. Sirolimus 0-9 interleukin 6 Mus musculus 20-33 28182002-5 2017 Rapamycin increased interleukin-6 (IL-6) expression, which was associated with reduced expression of inflammatory cytokines, indicating anti-inflammatory properties of IL-6 in the MPTP model. Sirolimus 0-9 interleukin 6 Mus musculus 35-39 28182002-5 2017 Rapamycin increased interleukin-6 (IL-6) expression, which was associated with reduced expression of inflammatory cytokines, indicating anti-inflammatory properties of IL-6 in the MPTP model. Sirolimus 0-9 interleukin 6 Mus musculus 168-172 27692982-4 2017 Although rapamycin did not affect the increase in body weight and adiposity, it exacerbated the glucose intolerance and adipose tissue inflammation induced by HFD feeding, as evidenced by the increased adipose tissue percentage of M1 macrophages, naive and activated cytotoxic T lymphocytes, and mRNA levels of proinflammatory molecules, such as TNF-alpha, IL-6 and MCP-1. Sirolimus 9-18 interleukin 6 Mus musculus 357-361 24742865-9 2014 Sunitinib plus rapamycin markedly induced versican, IDO, arginase 1, IL-6, and TGF-beta expression in the lungs, whereas it reduced IDO and IL-10 expression in the primary tumor tissues. Sirolimus 15-24 interleukin 6 Mus musculus 69-73 24742865-10 2014 IL-6 levels in the circulation were increased after rapamycin and combination therapies. Sirolimus 52-61 interleukin 6 Mus musculus 0-4 22040565-6 2011 Rapa reduced the levels of TNF-alpha (LPS vs. LPS + Rapa, (1672.74 +- 193.73) vs. (539.17 +- 140.48) pg/ml, respectively; P < 0.01) and IL-6 (LPS vs. LPS + Rapa: (7790.88 +- 1170.54) vs. (1968.57 +- 474.62) pg/ml, respectively; P < 0.01) in the BAL fluid. Sirolimus 0-4 interleukin 6 Mus musculus 139-143 23480027-7 2013 The therapeutic effects of sirolimus were associated with a down-regulation of pro-inflammatory cytokines tumour necrosis factor-alpha, IL-6 and IL-17A. Sirolimus 27-36 interleukin 6 Mus musculus 136-140 23426399-5 2013 IL-1, IL-3, IL-6, TNF-alpha, TGF-beta, PDGF, MCP-1 and MIP-1 expression were higher in rapamycin-treated mice compared to the control group, however, IGF-1 expression was lower. Sirolimus 87-96 interleukin 6 Mus musculus 12-16 23716625-9 2013 Two weeks after the chemical burn injury, a significant elevation in the corneal IL-6 levels of the positive control group was observed, compared to the levels in the negative control group or the rapamycin group (P < 0.05). Sirolimus 197-206 interleukin 6 Mus musculus 81-85 23716625-13 2013 Rapamycin protected the cornea from chemical damage via reduction of IL-6 and TGF-beta1 expression. Sirolimus 0-9 interleukin 6 Mus musculus 69-73 23105977-7 2012 Intranasal rapamycin attenuated lung MCP-1, IL-2, IL-6, and IFNgamma by 70%, 30%, 64%, and 68% respectively. Sirolimus 11-20 interleukin 6 Mus musculus 50-54 19220291-7 2009 Compared with placebo, plasma levels of interleukin-6, monocyte chemoattractant protein-1, interferon gamma, tumour necrosis factor alpha and CD40, and their mRNA levels in aortic tissue were significantly reduced in sirolimus-treated mice. Sirolimus 217-226 interleukin 6 Mus musculus 40-53 20506342-7 2010 The production of fibrogenic cytokines, such as interleukin-4 (IL-4), IL-6, IL-17, and transforming growth factor beta1, was attenuated by rapamycin. Sirolimus 139-148 interleukin 6 Mus musculus 70-74 19879324-4 2010 Rapamycin, an inhibitor of p70 S6 kinase, which attenuated the phosphorylation of p70 S6 kinase induced by TNF-alpha, significantly amplified the TNF-alpha-stimulated IL-6 synthesis. Sirolimus 0-9 interleukin 6 Mus musculus 167-171 20086156-3 2010 Stimulation of PMBC by SEB was effectively blocked by rapamycin as evidenced by the inhibition of tumor necrosis factor alpha (TNF-alpha), interleukin 1beta (IL-1beta), IL-6, IL-2, gamma interferon (IFN-gamma), monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1alpha (MIP-1alpha), MIP-1beta, and T-cell proliferation. Sirolimus 54-63 interleukin 6 Mus musculus 169-173 20086156-5 2010 The serum levels of MCP-1 and IL-6, after intranasal exposure to SEB, were significantly reduced in mice given rapamycin versus controls. Sirolimus 111-120 interleukin 6 Mus musculus 30-34 20005342-9 2009 Rapamycin treatment showed minimal effects on postischemic kidney fibrosis with variable effects on various cytokine/chemokine protein expressions, namely, decreasing interleukin (IL)-1alpha, IL-6, tumor necrosis factor (TNF)-alpha, and regulated on activation normal T cell expressed and secreted (RANTES) while increasing IL-4, keratinocyte-derived chemokine (KC), macrophage inflammatory protein (MIP-1alpha), and IL-10 in the ischemic kidney. Sirolimus 0-9 interleukin 6 Mus musculus 192-196 7520778-2 1994 In addition, rapamycin blocks the proliferative response of cell lines to a variety of hematopoietic growth factors, including interleukin-3 (IL-3), interleukin-6 (IL-6), granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), and kit ligand (KL), suggesting that it should be a strong inhibitor of hematopoiesis. Sirolimus 13-22 interleukin 6 Mus musculus 149-162 18480312-7 2008 A significant decrease in vascular endothelial growth factor-A and an increase in IL-6 were detected in kidneys of these rapamycin-treated mice. Sirolimus 121-130 interleukin 6 Mus musculus 82-86 18372239-2 2008 Rapamycin, an inhibitor of p70 S6 kinase, significantly enhanced the FGF-2-stimulated IL-6 synthesis in a dose-dependent manner. Sirolimus 0-9 interleukin 6 Mus musculus 86-90 17379004-5 2007 Rapamycin, an inhibitor of p70 S6 kinase, significantly enhanced the PDGF-BB-stimulated IL-6 synthesis. Sirolimus 0-9 interleukin 6 Mus musculus 88-92 7520778-2 1994 In addition, rapamycin blocks the proliferative response of cell lines to a variety of hematopoietic growth factors, including interleukin-3 (IL-3), interleukin-6 (IL-6), granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), and kit ligand (KL), suggesting that it should be a strong inhibitor of hematopoiesis. Sirolimus 13-22 interleukin 6 Mus musculus 164-168 33116044-10 2021 In addition, the clinical-mimicking dose of sirolimus reduced the thickness of the intestinal mucosal layer, increased the intestinal permeability, and enriched the circulating pro-inflammatory factors, including IL-12, IL-6, MCP-1, GM-CSF, and IL-1beta. Sirolimus 44-53 interleukin 6 Mus musculus 220-224 34065421-8 2021 Pathway analysis showed IL10 signaling as a major contributing pathway to the altered immunophenotype after Rapamycin treatment compared to vehicle with significantly lower cytokines Tnfa, Il1b, and Il6, while regulators of mitochondrial content Pgc1a, Tfam, and Ho1 remained elevated. Sirolimus 108-117 interleukin 6 Mus musculus 199-202 35058778-10 2021 Compared with MgIG treatment, activation of autophagy by RAPA also promoted the expression of liver inflammation markers (IL-1beta, IL-6, TNF-alpha, CXCL-1, CXCL-2, CXCL-10, etc.) Sirolimus 57-61 interleukin 6 Mus musculus 132-136 1987692-4 1991 Similarly, cyclosporine potentiated the inhibitory effects of rapamycin upon proliferation of IL-2 (CTLL-2) and IL-6 (MH60.BSF-2) lymphokine-dependent cell lines. Sirolimus 62-71 interleukin 6 Mus musculus 112-116 31231866-8 2019 Rapamycin mediated decrease of IL-6 secretion suggests a particular mechanistic target of rapamycin (mTOR)-IL-6 link and appeared to be microglia specific. Sirolimus 0-9 interleukin 6 Mus musculus 107-111 32567086-10 2021 Inhibitors of MEK1/2 (PD98059), JNK (SP600125), upstream kinase of p70 S6 kinase (rapamycin) and Akt (deguelin), all increased IL-6 release. Sirolimus 82-91 interleukin 6 Mus musculus 127-131 33350241-14 2020 As compared with the 3 MA group, the number of activities, ChAT, TH, and p62 expression levels were significantly reduced in the low and medium dose piperine groups and rapamycin group(P<0.05); howe-ver, their first foot licking time was significantly prolonged, APP, p-tau, IL-6, TNF-alpha, alpha-syn, beclin-1, LC3 B and mmu-miR-99 a-5 p expression levels were increased significantly(P<0.05). Sirolimus 169-178 interleukin 6 Mus musculus 275-279 33350241-15 2020 As compared with the medopar group, the number of activities, ChAT, TH, and p62 expression levels were significantly reduced in low dose piperine group and rapamycin group(P<0.05), but their first foot licking time was significantly extended, and APP, p-tau, IL-6, TNF-alpha, alpha-syn, beclin-1, LC3 B and mmu-miR-99 a-5 p expression levels were significantly increased(P<0.05). Sirolimus 156-165 interleukin 6 Mus musculus 259-263 31803045-10 2019 Melatonin and rapamycin significantly ameliorated the isoflurane-induced cognitive impairment and also led to a decrease in the melatonin levels as well as the expression levels of TNF-alpha, IL-1beta, IL-6, and p-mTOR in the hippocampus. Sirolimus 14-23 interleukin 6 Mus musculus 202-206 31231866-7 2019 Rescuing autophagy by treatment with rapamycin was sufficient to decrease interleukin 6 (IL-6) but not tumor necrosis factor (TNF) secretion in cultured microglia. Sirolimus 37-46 interleukin 6 Mus musculus 74-87 31231866-7 2019 Rescuing autophagy by treatment with rapamycin was sufficient to decrease interleukin 6 (IL-6) but not tumor necrosis factor (TNF) secretion in cultured microglia. Sirolimus 37-46 interleukin 6 Mus musculus 89-93 31231866-8 2019 Rapamycin mediated decrease of IL-6 secretion suggests a particular mechanistic target of rapamycin (mTOR)-IL-6 link and appeared to be microglia specific. Sirolimus 0-9 interleukin 6 Mus musculus 31-35